(Q38846832)

7 September 2017

1 reference

title

Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). (English)

1 reference

7 September 2017

1 reference

Sandy Elbitar

1

0 references

Youmna Ghaleb

Youmna Ghaleb

3

0 references

Jean-Pierre Rabès

Jean-Pierre Rabès

4

0 references

Mathilde Varret

Mathilde Varret

5

0 references

Catherine Boileau

Catherine Boileau

7

0 references

Nabil Seidah

Nabil G Seidah

6

0 references

Marianne Abifadel

8

Marianne Abifadel

1 reference

7 September 2017

2

Petra El Khoury

1 reference

7 September 2017

language of work or name

English

0 references

publication date

30 June 2016

1 reference

Expert Opinion on Therapeutic Patents

7 September 2017

published in

1 reference

7 September 2017

volume

26

1 reference

7 September 2017

issue

12

1 reference

7 September 2017

page(s)

1377-1392

1 reference

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Familial hypercholesterolaemia in Portugal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Characterization of novel mutations in the catalytic domain of the PCSK9 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

PCSK9: a key modulator of cardiovascular health

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

A new method for measurement of total plasma PCSK9: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Berberine decreases PCSK9 expression in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Combination of simvastatin with berberine improves the lipid-lowering efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Understanding PCSK9 and anti-PCSK9 therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

A cholesterol-lowering VLP vaccine that targets PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Molecular basis for LDL receptor recognition by PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2016.1206080

10.1080/13543776.2016.1206080

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference